Insider Selling: Pulmonx (NASDAQ:LUNG) Insider Sells $11,056.76 in Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 7,732 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total transaction of $11,056.76. Following the completion of the sale, the insider owned 365,734 shares of the company’s stock, valued at approximately $522,999.62. The trade was a 2.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Pulmonx Trading Up 25.5%

Shares of LUNG opened at $2.02 on Friday. The stock’s 50-day moving average price is $1.75 and its 200 day moving average price is $1.79. The company has a quick ratio of 4.15, a current ratio of 4.86 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $83.33 million, a price-to-earnings ratio of -1.52 and a beta of 0.07. Pulmonx Corporation has a 12-month low of $1.31 and a 12-month high of $8.12.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.14. Pulmonx had a negative return on equity of 78.35% and a negative net margin of 59.67%.The company had revenue of $22.60 million during the quarter, compared to the consensus estimate of $21.73 million. As a group, research analysts predict that Pulmonx Corporation will post -1.55 earnings per share for the current year.

Institutional Investors Weigh In On Pulmonx

Several large investors have recently made changes to their positions in LUNG. Cerity Partners LLC acquired a new stake in shares of Pulmonx during the 4th quarter worth about $27,000. FNY Investment Advisers LLC acquired a new position in Pulmonx in the third quarter valued at about $29,000. Opal Capital LLC bought a new stake in Pulmonx during the fourth quarter worth about $29,000. Regatta Capital Group LLC acquired a new stake in shares of Pulmonx during the fourth quarter worth approximately $30,000. Finally, Jain Global LLC acquired a new stake in shares of Pulmonx during the third quarter worth approximately $30,000. Institutional investors own 91.04% of the company’s stock.

Key Stories Impacting Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx beat Q4 expectations — EPS -$0.25 vs. consensus ~- $0.39 and revenue $22.6M vs. ~$21.7M; net loss narrowed and adjusted EBITDA improved year‑over‑year, signaling operational progress. Read More.
• Positive Sentiment: Closed a five‑year senior secured credit facility with Perceptive Advisors (initial $40M draw; up to $60M total subject to milestones), which refinanced prior debt and extends maturities to 2031 — materially improves near‑term liquidity. Read More.
• Positive Sentiment: Gross margin and cost discipline improved — Q4 gross margin ~78% and operating expenses down ~11% vs. prior year quarter, supporting a clearer path toward profitability if revenue momentum returns. Read More.
• Positive Sentiment: D. Boral Capital reaffirmed a Buy rating (high target), which can attract momentum buyers given large upside vs. current levels. Read More.
• Neutral Sentiment: Management outlined a strategic restructuring and sales‑force changes on the earnings call — intended to re‑accelerate commercial growth but the near‑term impact on procedure volumes is unclear. Read More.
• Neutral Sentiment: Some analysts updated targets (Canaccord trimmed its target but kept a Buy rating) — mixed analyst activity keeps coverage but shows differing views on recovery timing. Read More.
• Negative Sentiment: 2026 revenue guidance of $90M–$92M came in below consensus (~$94M), implying slower top‑line growth and limiting near‑term upside despite margin improvements. Read More.
• Negative Sentiment: Insider selling was reported (CEO, general counsel and other officers sold shares on March 2), which can increase perceived selling pressure and weigh on sentiment. Read More.
• Negative Sentiment: The new loan carries a high effective cost (SOFR + 7.0% with 3.75% floor and a 2% PIK option) and includes warrants — helpful for liquidity but increases interest burden and potential dilution if exercised. Read More.

Analysts Set New Price Targets

A number of research firms have weighed in on LUNG. D. Boral Capital reiterated a “buy” rating and set a $14.00 price target on shares of Pulmonx in a research note on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pulmonx in a report on Thursday, January 22nd. Canaccord Genuity Group lowered their target price on shares of Pulmonx from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Five analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.38.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.